Spring Bank Pharmaceuticals Inc SBPH, a micro cap clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of viral infections, opened at $11.28 on Friday, 6 percent below the IPO price, which was set at $12.00 per share. Trading is scheduled to commence next Wednesday, May 11, under the SBPH symbol, in the Nasdaq exchange.
Earlier in the day, the firm had priced its IPO of 920,000 shares at $12, even though the original plan was to offer 2.858 million shares for $13 to $15 each. All of these shares are being offered by Spring Bank, which has also granted its underwriter, Dawson James Securities, Inc., the option to buy, over the next 30 days, an additional 138,000 shares from the company.
Related Link: IPO Outlook: Do 4 Biotechs Mean Maybe The IPO Market Is Back?
The company expected to receive about $8.2 million (after discounts and commissions) from the IPO, and planned to use the money to fund a clinical trial and other corporate operations.
Shares of Spring Bank Pharmaceuticals were trading around $11.26, down 6.17 percent on Friday afternoon.
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
